Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$18.84 USD
-0.38 (-1.98%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $18.89 +0.05 (0.27%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELVN 18.84 -0.38(-1.98%)
Will ELVN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
Other News for ELVN
BlackRock, Inc. Reduces Stake in Enliven Therapeutics Inc.
Enliven Therapeutics Inc Breaks Above 200-Day Moving Average - Bullish for ELVN
COMMODORE CAPITAL LP Acquires 1,175,000 Shares in Cidara Therapeutics Inc
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday
Enliven Therapeutics (ELVN) Receives Raised Price Target from HC Wainwright & Co. ...